logo-loader
Anavex Life Sciences

Anavex Life Sciences advancing its Parkinson's disease therapy through the pipeline

Anavex Life Sciences Corp (NASDAQ:AVXL) President and CEO Christopher Missling sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biopharmaceutical company is developing therapeutics to treat neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, pain, and various types of cancer.

Quick facts: Anavex Life Sciences

Price: $2.71

Market: NASDAQ
Market Cap: $142.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

1 day, 9 hours ago

2 min read